Glucagon-like peptide-1 receptor agonists and risk of diabetic retinopathy in type 2 diabetes: A systematic review and network meta-analysis of randomized clinical trials.
A comprehensive analysis clarifies how different diabetes medications affect eye complications, helping doctors and patients make informed choices about which GLP-1 drugs to use.
This systematic review and network meta-analysis synthesizes randomized trial evidence on diabetic retinopathy risk across GLP-1 receptor agonist classes in type 2 diabetes, providing comparative estimates needed to inform prescribing decisions for the large and growing GLP-1RA-treated population. The findings directly address an unresolved safety signal relevant to cardiometabolic prescribers and ophthalmologists managing patients initiating GLP-1RA therapy.
What the study was
- Study design
- Systematic review and network meta-analysis of randomized clinical trials
- Population
- Adults with type 2 diabetes mellitus enrolled in RCTs of GLP-1 receptor agonists
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Survey of ophthalmology
Why it surfaced
Network meta-analysis of RCTs directly addressing clinically important GLP-1RA safety question (diabetic retinopathy risk) for a large and rapidly growing treatment population; highest design quality evidence type (NMA of RCTs). Classification confidence=medium as abstract not retrieved via efetch.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.